ASCO 2016 Annual Meeting

Dabrafenib Plus Trametinib Continue to Show Survival Benefit in BRAF-mutant Metastatic Melanoma

The longest overall survival follow-up among randomized phase 3 trials evaluating BRAF and MEK inhibitors in patients with BRAF-mutant metastatic melanoma to date has shown the best 3-year outcome with dabrafenib plus trametinib to be in patients with normal LDH and fewer than 3 disease sites, according to a presentation at the ASCO 2016 Annual Meeting.

Next post in ASCO 2016 Annual Meeting